Related references
Note: Only part of the references are listed.Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
Yuya Seko et al.
HEPATOLOGY RESEARCH (2017)
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Akio Ohta et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study
Hiroshi Tobita et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects
Takahiro Takase et al.
ENDOCRINE JOURNAL (2017)
Effects of a Sodium-Glucose Cotransporter 2 Inhibitor in Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus: Preliminary Prospective Study Based On Serial Liver Biopsies
Norio Akuta et al.
HEPATOLOGY COMMUNICATIONS (2017)
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
Kento Imajo et al.
GASTROENTEROLOGY (2016)
Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
Teruo Jojima et al.
DIABETOLOGY & METABOLIC SYNDROME (2016)
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
Siddharth Singh et al.
HEPATOLOGY (2015)
Nonalcoholic Fatty Liver Disease: Portal Hypertension Due to Outflow Block in Patients without Cirrhosis
Masashi Hirooka et al.
RADIOLOGY (2015)
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats
Masanori Yokono et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Doppler Assessment of Splanchnic Arterial Flow in Patients with Liver Cirrhosis: Correlation with Ammonia Plasma Levels and MELD Score
Tijana M. Glisic et al.
JOURNAL OF CLINICAL ULTRASOUND (2014)
Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations
Victor de Ledinghen et al.
JOURNAL OF HEPATOLOGY (2014)
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
Atsuo Tahara et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2014)
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
J. P. H. Wilding et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
Atsuo Tahara et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases
Hironori Ochi et al.
HEPATOLOGY (2012)
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Naga Chalasani et al.
HEPATOLOGY (2012)
Early Detection of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver Disease by Using MR Elastography
Jun Chen et al.
RADIOLOGY (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
SGLT2 inhibition - a novel strategy for diabetes treatment
Edward C. Chao et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Diagnostic criteria for Dyslipidemia - Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese
Tamio Teramoto et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2007)
Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH
Y Yoshioka et al.
JOURNAL OF GASTROENTEROLOGY (2004)
Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background
S Kojima et al.
JOURNAL OF GASTROENTEROLOGY (2003)
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
G Marchesini et al.
HEPATOLOGY (2003)
Transient elastography: A new noninvasive method for assessment of hepatic fibrosis
L Sandrin et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2003)
Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis
M Shimada et al.
JOURNAL OF HEPATOLOGY (2002)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
Share Paper
